By targeting Stat3, we may directly inhibit Stat3-dependent drug resistant mechanisms and inhibit Stat3-independent drug resistant mechanisms indirectly by decreasing IL-6 autocrine production in cancer cells simultaneously. Here, IL6 is linked to cancer.